title: Patient Stage of Change predicts outcome in a panic disorder medication trial.
abstract: OBJECTIVE
  The authors test the hypothesis that patient readiness to change predicts outcome in a placebo-controlled medication trial.
  
  
  METHODS
  Out-patients with panic disorder and agoraphobia completed the Stages of Change (SOC) questionnaire, a measure of readiness to change, before being randomly assigned either sustained release (SR) adinazolam or placebo in a 4 week double-blind trial.
  
  
  RESULTS
  In the "intent to treat" analysis, for the 202 subjects who made at least one visit after baseline, adinazolam SR was significantly more effective than placebo on most major outcome measures. Of the 126 subjects who completed the SOC questionnaire, regression analyses showed significant correlations between SOC scores and all 5 outcome measures. In a second analysis, cluster membership based on SOC scores was predictive of outcome on 3 of 5 measures. In each statistical analysis, subjects who were not predisposed to change as measured by the SOC were significantly less likely to change.
  
  
  CONCLUSIONS
  Patient readiness to change was strongly correlated with outcome in a placebo-controlled panic disorder trial with an effective medication. In this study, the SOC category, Precontemplation (i.e., those subjects who reported the belief that they had no problem) were less likely to change compared to those who believed that they had a problem.
authors.affiliation: Department of Psychiatry and Neurology, University of Missouri, Columbia School of Medicine, Columbia, USA.
authors.forename: B D
authors.initials: BD
authors.lastname: Beitman
authors.forename: N C
authors.initials: NC
authors.lastname: Beck
authors.forename: W E
authors.initials: WE
authors.lastname: Deuser
authors.forename: C S
authors.initials: CS
authors.lastname: Carter
authors.forename: J R
authors.initials: JR
authors.lastname: Davidson
authors.forename: R J
authors.initials: RJ
authors.lastname: Maddock
mesh_terms: D000379:Agoraphobia / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D014151:Anti-Anxiety Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009042:Motivation; D016584:Panic Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D010342:Patient Acceptance of Health Care; D010555:Personality Inventory; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; C039668:adinazolam